Attached files
| file | filename |
|---|---|
| EX-32 - EX-32.1 - Verve Therapeutics, Inc. | verv-20210630ex32_1.htm |
| EX-31 - EX-31.2 - Verve Therapeutics, Inc. | verv-20210630ex31_2.htm |
| EX-31 - EX-31.1 - Verve Therapeutics, Inc. | verv-20210630ex31_1.htm |
| 10-Q - 10-Q - Verve Therapeutics, Inc. | verv-q2-2021.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Verve Therapeutics, Inc. (the “Company”) for the period ending June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Andrew Ashe, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: August 12, 2021 |
|
By: |
/s/ Andrew Ashe |
|
|
|
Andrew Ashe, J.D. |
|
|
|
President and Chief Operating Officer |
|
|
|
(Principal Financial Officer) |